Qianjin Liao Selected Research

Messenger RNA (mRNA)

4/2024	CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair.
11/2022	Circular RNA circCCNB1 inhibits the migration and invasion of nasopharyngeal carcinoma through binding and stabilizing TJP1 mRNA.
1/2022	Construction of a lncRNA-mRNA Co-Expression Network for Nasopharyngeal Carcinoma.
1/2022	Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics.
1/2021	CircARHGAP12 promotes nasopharyngeal carcinoma migration and invasion via ezrin-mediated cytoskeletal remodeling.
12/2020	EBV-miR-BART12 accelerates migration and invasion in EBV-associated cancer cells by targeting tubulin polymerization-promoting protein 1.
3/2016	An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma.
1/2016	HYOU1, Regulated by LPLUNC1, Is Up-Regulated in Nasopharyngeal Carcinoma and Associated with Poor Prognosis.
1/2013	Prohibitin is an important biomarker for nasopharyngeal carcinoma progression and prognosis.
9/2011	NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qianjin Liao Research Topics

Disease

92	Neoplasms (Cancer) 05/2024 - 05/2011
26	Nasopharyngeal Carcinoma 04/2024 - 09/2011
25	Carcinogenesis 05/2024 - 09/2011
24	Neoplasm Metastasis (Metastasis) 01/2024 - 01/2013
6	Ovarian Neoplasms (Ovarian Cancer) 04/2023 - 02/2019
6	Colonic Neoplasms (Colon Cancer) 03/2023 - 01/2017
5	Lung Neoplasms (Lung Cancer) 06/2022 - 01/2016
5	Stomach Neoplasms (Stomach Cancer) 06/2022 - 09/2014
4	Colorectal Neoplasms (Colorectal Cancer) 01/2024 - 02/2013
4	Fibrosis (Cirrhosis) 01/2022 - 01/2019
3	Breast Neoplasms (Breast Cancer) 06/2022 - 06/2018
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2022 - 01/2017
3	Infections 01/2022 - 09/2014
3	Prostatic Neoplasms (Prostate Cancer) 04/2021 - 07/2014
2	Glioma (Gliomas) 01/2023 - 05/2011
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2022 - 04/2019
2	Esophageal Squamous Cell Carcinoma 08/2022 - 09/2021
2	Urinary Bladder Neoplasms (Bladder Cancer) 06/2022 - 01/2020
2	Disease Progression 01/2022 - 06/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2018
2	Hypoxia (Hypoxemia) 01/2021 - 09/2020
2	Inflammation (Inflammations) 06/2016 - 01/2012
2	Epstein-Barr Virus Infections 01/2016 - 12/2015
1	Carcinoma (Carcinomatosis) 01/2024
1	Ascites 04/2023
1	Bacterial Infections (Bacterial Infection) 01/2023
1	Glioblastoma (Glioblastoma Multiforme) 08/2022

Drug/Important Bio-Agent (IBA)

25	Proteins (Proteins, Gene)FDA Link 04/2024 - 09/2011
20	Biomarkers (Surrogate Marker)IBA 01/2023 - 05/2011
18	Long Noncoding RNAIBA 08/2022 - 08/2015
14	MicroRNAs (MicroRNA)IBA 10/2021 - 05/2011
12	RNA (Ribonucleic Acid)IBA 05/2024 - 01/2017
12	Circular RNAIBA 01/2023 - 01/2017
10	Messenger RNA (mRNA)IBA 04/2024 - 09/2011
6	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 05/2019
5	CytokinesIBA 01/2023 - 01/2012
5	Cadherins (E-Cadherin)IBA 02/2019 - 01/2016
5	VimentinIBA 02/2019 - 01/2016
4	diallyl disulfide (diallyl disulphide)IBA 01/2024 - 02/2013
4	Transcription Factors (Transcription Factor)IBA 03/2023 - 01/2022
3	EnzymesIBA 01/2024 - 01/2012
3	Small Cytoplasmic RNAIBA 10/2023 - 03/2021
3	Conditioned Culture MediaIBA 04/2023 - 01/2012
3	ProhibitinsIBA 03/2023 - 01/2013
3	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2022
3	VaccinesIBA 01/2023 - 08/2022
3	Phosphotransferases (Kinase)IBA 01/2022 - 01/2013
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2018
2	Untranslated RNA (Noncoding RNA)IBA 01/2024 - 10/2022
2	CollagenIBA 01/2024 - 01/2021
2	Amino Acids FDA Link 01/2024 - 01/2023
2	IronIBA 01/2024 - 10/2022
2	LipidsIBA 01/2024 - 01/2023
2	TNF Receptor-Associated Factor 4IBA 02/2023 - 01/2023
2	Adenosine Triphosphate (ATP)IBA 06/2022 - 01/2022
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2022 - 01/2021
2	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 01/2022 - 01/2017
2	TensinsIBA 01/2022 - 01/2017
2	Competitive Endogenous RNAIBA 01/2022 - 10/2018
2	AndrogensIBA 04/2021 - 03/2018
2	Hormones (Hormone)IBA 04/2021 - 01/2020
2	SmokeIBA 01/2021 - 01/2021
2	Antisense RNA (Anti-Sense RNA)IBA 01/2021 - 10/2018
2	3' Untranslated Regions (3' UTR)IBA 01/2021 - 12/2020
2	ParaffinIBA 01/2021 - 01/2016
2	Hydroxyproline (4 Hydroxyproline)IBA 10/2020 - 01/2019
2	Small Interfering RNA (siRNA)IBA 02/2019 - 07/2014
2	Botulinum Toxins (Botulinum Toxin)IBA 01/2019 - 01/2016
2	Complementary DNA (cDNA)IBA 08/2015 - 01/2013
1	N-methyladenosineIBA 05/2024
1	6-methyladenineIBA 05/2024
1	Prokaryotic Initiation Factor-3IBA 04/2024
1	PolyaminesIBA 01/2024
1	SeleniumIBA 01/2024
1	CateninsIBA 12/2023
1	NF-kappa B (NF-kB)IBA 12/2023
1	Progesterone FDA LinkGeneric 04/2023
1	rac1 GTP-Binding ProteinIBA 03/2023
1	Ubiquitin-Specific Peptidase 7IBA 02/2023
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 01/2023
1	Docetaxel (Taxotere)FDA Link 01/2023
1	Histones (Histone)IBA 01/2023
1	Hydroxyl RadicalIBA 10/2022
1	IonsIBA 10/2022
1	Chimeric Antigen ReceptorsIBA 09/2022
1	Monoclonal AntibodiesIBA 09/2022
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 06/2022
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 06/2022
1	Matrix Metalloproteinases (MMPs)IBA 03/2022
1	LycopeneIBA 02/2022
1	B7-H1 AntigenIBA 02/2022
1	Zinc Finger E-box-Binding Homeobox 1IBA 02/2022
1	chondroitin sulfate proteoglycan 4IBA 02/2022

Therapy/Procedure

26	Therapeutics 05/2024 - 05/2011
11	Immunotherapy 05/2024 - 01/2018
8	Radiotherapy 04/2024 - 01/2016
8	Drug Therapy (Chemotherapy) 01/2024 - 01/2018
2	Castration 04/2021 - 03/2018
2	Aftercare (After-Treatment) 01/2020 - 06/2018
1	Adjuvant Chemotherapy 02/2022